Search Within

Survivorship Research

Formats
  1. Journal Article (9016)
  2. Meeting Abstract (5248)
  3. Book Section (579)
  4. Review (367)
  5. Editorial (234)
  6. Research Letter (138)
  7. Conference Paper (104)
  8. Correspondence (92)
  9. Guidelines (90)
  10. Miscellaneous (78)
  11. Book Whole (30)
Groups
  1. Department of Medicine (9330)
  2. Population Sciences Research Program (5762)
  3. Solid Tumor Oncology Division (5247)
  4. Surgery (5206)
  5. Epidemiology and Biostatistics (3671)
  6. Division of Subspecialty Medicine (3269)

More Groups

People
  1. Clifford Hudis (905)
  2. Kenneth Offit (792)
  3. Michael Zelefsky (755)
  4. Sergio Giralt (703)
  5. Mark Robson (682)
  6. Joachim Yahalom (634)

More People

Years
  1. 2025 (396)
  2. 2024 (844)
  3. 2023 (892)
  4. 2022 (906)
  5. 2021 (922)
  6. 2020 (933)

More Years

Publications
  1. Journal of Clinical Oncology (1892)
  2. International Journal of Radiation Oncology, Biology, Physics (912)
  3. Blood (723)
  4. Annals of Surgical Oncology (604)
  5. Cancer (334)
  6. Cancer Research (333)

More Publications

Publishers
  1. Elsevier Inc. (2394)
  2. American Society of Clinical Oncology (2041)
  3. Springer (1562)
  4. Wiley Blackwell (821)
  5. Oxford University Press (792)
  6. American Society of Hematology (791)

More Publishers

Results (15976)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Evolving consolidation patterns and modern outcomes for a large longitudinal cohort of primary CNS lymphoma patients
    Meeting Abstract

    Imber, B. S.; Tringale, K.; White, C.; Zhang, Z.; Scordo, M.; Yahalom, J.; Grommes, C.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Radiotherapy as an effective bridge for chemo‐refractory or progressive secondary CNS lymphoma
    Meeting Abstract

    Cederquist, G.; Tringale, K.; Hajj, C.; Hubbeling, H.; Sarkar, R.; Ma, J.; Dreyfuss, A.; Fregonese, B.; Lee, J.; Salles, G.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Genomic correlates of radiosensitivity in diffuse large B cell lymphoma
    Meeting Abstract

    Sarkar, R. R.; Ma, J.; Wijetunga, N. A.; Salles, G.; Joffe, E.; Imber, B.; Yahalom, J.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Genetic alterations in follicular lymphoma predict response to very low dose radiotherapy
    Meeting Abstract

    Wijetunga, N. A.; Lebow, E.; Chan, A.; Lee, J.; Fregonese, B.; Hajj, C.; Cedarquist, G.; Hubbeling, H.; Ma, J.; Sarkar, R.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Very low dose radiation therapy for indolent lymphoma: Comparing "Big Boom" (4GY × 1) versus "Boom Boom" (2GY × 2)
    Meeting Abstract

    Hajj, C.; Lee, J.; Boe, L.; Fregonese, B.; Lebow, E.; Wijetunga, N. A.; Hubbeling, H.; Tringale, K.; Freret, M.; Imber, B.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A. M.; Noy, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Impact of response to systemic bridging therapy on clinical outcomes and cytokine profile in patients receiving CAR T‐cell therapy for aggressive B‐cell lymphoma
    Meeting Abstract

    Wills, B.; Shouval, R.; Flynn, J.; Devlin, S. M.; Shah, G. L.; Scordo, M.; Dahi, P. B.; Lin, R. J.; Imber, B.; Parascondola, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • BRCA1/2 mutations impact on the development of breast implant‐associated lymphoma (BIA‐ALCL) in women with breast cancer reconstructed with textured breast implants
    Meeting Abstract

    Ghione, P.; Arcila, M.; Joseph, V.; Dogan, A.; Cordeiro, P.; Salles, G.; de Jong, D.; Horwitz, S.; Mandelker, D.; van Leeuwen, F.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save